1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A.

SDMHF
Sartorius Stedim Biotech S.A.US flagOther OTC
191.50
USD
- -
- -
18.63BMarket Cap
Sartorius Stedim Biotech S.A.
SDMHF
(Other OTC)

Recent

price

191.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.49
5.19
5.91
6.39
7.42
9.59
11.41
11.73
13.15
15.63
20.72
31.32
37.9
30.12
28.74
30.5
29.49
Revenue per Share
0.4
0.47
0.62
0.72
0.79
1.28
1.67
1.75
2.26
2.54
3.64
4.5
9.51
3.37
1.81
2.73
2.29
Basic EPS, GAAP
0.58
0.24
0.11
0.98
0.7
0.97
0.83
0.52
0.55
1.89
2.8
4.1
6.64
2.96
4.91
3.07
5.06
Free Cash Flow per Basic Share
0.11
0.15
0.17
0.18
0.2
0.22
0.33
0.42
0.46
0.57
0.34
0.68
1.26
1.44
0.69
0.69
- -
Dividend per Share
0.9
1.26
1.67
2.17
3.23
4.41
5.71
6.95
8.73
10.06
13.09
15.36
24.06
26.12
26.49
27.41
26.27
Book Value per Share
0.13
0.46
0.42
0.61
1.22
1.81
2.98
3.48
5.24
6.1
1.78
2.47
5.43
-20.67
-5.33
-3.02
-4.25
Tangible Book Value per Share
96
92
92
92
92
92
92
92
92
92
92
92
92
92
97
97
98
Basic Weighted Avg Shares
433
477
544
588
684
884
1,052
1,081
1,212
1,441
1,910
2,887
3,493
2,776
2,780
2,968
2,896
Sales/Revenue/Turnover
13.83
16.36
16.97
17.92
17.92
22.35
22.99
23.25
23.72
24.2
26.36
30.59
30.21
16.98
14.3
18.18
15.64
Operating Margin (%)
23
24
26
31
36
40
45
51
61
73
102
142
182
237
302
318
312
Depreciation Expense
39
43
57
66
72
118
154
161
208
235
336
414
876
310
175
266
225
Net Income, GAAP
31.22
33.21
29.29
28.56
29.87
29.58
26.81
25.77
26.21
25.64
26.5
35.94
22.16
22.19
18.57
28.75
20.32
Effective Tax Rate (%)
8.9
9.02
10.43
11.26
10.6
13.34
14.61
14.9
17.16
16.28
17.59
14.35
25.08
11.18
6.3
8.95
7.78
Profit Margin (%)
31
52
-5
103
47
78
147
140
171
208
306
418
635
478
802
29
861
Working Capital
92
104
36
137
33
30
26
62
58
84
563
585
1,112
3,603
2,805
2,019
2,836
LT Debt
365
396
435
482
539
647
764
879
1,045
1,189
1,461
1,733
2,514
2,674
4,024
4,126
4,039
Total Equity
7.77
9.7
11.35
12.15
13.15
19.32
21.16
19.06
18.46
19.91
21.17
24.36
25.73
7.05
4.77
5.56
5.13
Return on Invested Capital (%)
19.94
19.25
21.21
20.57
19.39
25.41
26.57
22.43
23.62
22.96
23.23
21.41
32.03
8.36
5.06
6.77
6.14
Return on Capital (%)
54.53
42.54
42.19
37.54
29.15
33.54
32.95
27.61
28.79
27.08
31.49
31.61
48.22
13.42
7.05
10.16
8.93
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
65
90
133
LT Borrowings
2,684
2,684
2,684
LT Finance Leases
121
159
152
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
97
97
Market Capitalization
18,236
18,273
19,487

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,741
1,780
1,807
Cash, Cash Equivalents & STI
689
727
745
Accounts Receivable, Net
248
267
264
Inventories
685
684
694
Total Current Liabilities
939
965
946
Payables & Accruals
- -
- -
- -
ST Debt
65
90
133
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.17%
24.61%
2.54%
Free Cash Flow
33.54%
18.07%
-37.09%
Net Income, GAAP
19.85%
15.66%
51.68%
Sales/Revenue/Turnover
14.38%
11.7%
6.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
667
706
655
751
2,780
2025
745
745
772
- -
2,968
2026
762
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.58
0.5
0.26
- -
1.81
2025
0.88
0.69
- -
- -
2.73
2026
0.91
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.69
2025
- -
- -
- -
- -
0.69
2026
- -
- -
- -
- -
- -
Similar Companies
Nyxoah S.A. (NYXH)
Bioelectronics Corporation (BIEL)
ChromoCure, Inc. (KKUR)
Dermisonics, Inc. (DMSI)
Helyx Industries S.p.A. (HLX.MI)
Micro-X Limited (MX1.AX)
Business
Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech S.A. is a leading international partner to the biopharmaceutical industry that provides equipment, consumables and services for the development, quality assurance and production of biologics, vaccines and other biotech medications. The company offers a comprehensive portfolio covering the entire bioprocess value chain, including cell line technologies, cell culture media, single-use bioreactors, tangential flow filtration systems, chromatography solutions, purification and concentration products for biological intermediates, single-use bags and systems for storage and transportation, as well as data analytics software for process modeling and optimization; it also supplies laboratory products such as analytical balances, pipettes and filtration systems for research and development in drug discovery, cell biology and molecular biology. Founded in 1978 as Stedim and merged in 2007 with Sartorius AG's biotech division to form the current entity, Sartorius Stedim Biotech S.A. is headquartered in Aubagne, France, with manufacturing and R&D sites, sales offices and subsidiaries in more than 30 countries across Europe, North America, Asia and other regions, employing around 9,900 to 10,600 people worldwide and generating approximately 2.8 billion euros in sales revenue in 2024. The company operates primarily through its Bioprocess Solutions segment focused on integrated solutions for upstream and downstream manufacturing in oncology, immunology, rare diseases and cell and gene therapies, complemented by a Lab Products & Services segment. Recent developments include strategic partnerships such as the 2025 alliance with Nanotein Technologies involving a minority investment of up to 3 million US dollars for exclusive distribution and joint development of NanoSpark immune cell activation reagents for cell and gene therapy, as well as a collaboration with Bio Usawa Biotechnology to enable biopharmaceutical manufacturing in Africa through technology transfer, process optimization and supply of bioprocessing equipment, media, buffers and consumables; Sartorius Stedim Biotech continues long-term investments in production capacity expansion, particularly in North America and Asia, alongside ongoing acquisitions of complementary technologies to enhance single-use solutions, automation and sustainability initiatives targeting an underlying EBITDA margin above 35 percent by 2028.

Company News

APIChatGPT

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SRTOY) Q4 2025 Earnings Call Transcript

  • businesswire.com

    Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing

  • globenewswire.com

    Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

  • businesswire.com

    Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform

  • reuters.com

    Sartorius, Sartorius Stedim Biotech shares jump after results beat

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SDMHF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call Transcript

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SDMHF) Q4 2023 Earnings Call Transcript

  • marketwatch.com

    10 stocks for investors looking for ‘wonderful companies at a fair price'

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SDMHF) Q3 2023 Earnings Call Transcript

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SDMHF) Q2 2023 Earnings Call Transcript

  • marketwatch.com

    Sartorius, Sartorius Stedim shares fall after Polyplus acquisition

  • seekingalpha.com

    Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Call Transcript